RSV is a common respiratory virus; nirsevimab is an antibody (not a vaccine) that protects babies.
Respiratory syncytial virus (RSV) causes respiratory infections in almost all children by age 2 and, in infants, can cause bronchiolitis and pneumonia. Nirsevimab is a monoclonal antibody, that is, it is not a vaccine: it gives direct protection during the virus season. In the 2026-2027 season, from 16 September 2026 to 31 March 2027, it is recommended and free for all children born between 1 April 2026 and 31 March 2027: at birth, in the maternity unit, for those born from 16 September 2026 (those born earlier had a catch-up until 30 October 2026), and also for some risk groups. It is voluntary, and the rules change each season: ask at the maternity unit or your paediatrician.
Source: DGS, Norma n.º 004/2026, of 02/09/2026 — https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0042026-de-02092026-campanha-de-imunizacao-sazonal-contra-o-virus-sincicial-respiratorio-vsr-em-idade-pediatrica-outono-inverno-2026-2027.aspx ; Livro Azul de Vacinas, ch. 43